menu
    • menu
    [{"orgOrder":0,"company":"Yerevan State Medical University","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ARMENIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Perindopril","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Yerevan State Medical University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yerevan State Medical University \/ Servier","highestDevelopmentStatusID":"11","companyTruncated":"Yerevan State Medical University \/ Servier"},{"orgOrder":0,"company":"Academisch Ziekenhuis Maastricht","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Perindopril","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Academisch Ziekenhuis Maastricht","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Ziekenhuis Maastricht \/ ZonMw","highestDevelopmentStatusID":"11","companyTruncated":"Academisch Ziekenhuis Maastricht \/ ZonMw"},{"orgOrder":0,"company":"Pharmtechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELARUS","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Perindopril","moa":"Angiotensin-converting enzyme","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pharmtechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharmtechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pharmtechnology \/ Undisclosed"},{"orgOrder":0,"company":"Pharmtechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELARUS","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Perindopril","moa":"Angiotensin-converting enzyme","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pharmtechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharmtechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pharmtechnology \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for CAS-82834-16-0

    Menu

    CAS-82834-16-0

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Academisch Ziekenhuis Maastricht

                            Country arrow
                            FNCE
                            Not Confirmed

                            Academisch Ziekenhuis Maastricht

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Perindopril

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : ZonMw

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Timely Recovery After Subclinical Heart Failure

                            Details : Perindopril is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Heart Failure.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 02, 2024

                            Lead Product(s) : Perindopril

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : ZonMw

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pharmtechnology

                            Belarus arrow
                            FNCE
                            Not Confirmed

                            Pharmtechnology

                            Belarus arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Perindopril

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Perindopril Tablets in Healthy Volunteers Under Fasting Conditions

                            Details : Perindopril is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 19, 2024

                            Lead Product(s) : Perindopril

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pharmtechnology

                            Belarus arrow
                            FNCE
                            Not Confirmed

                            Pharmtechnology

                            Belarus arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Perindopril

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Perindopril /Amlodipine/Indapamide 8 mg (10 mg)/2.5 mg/10 mg Tablets in Healthy Volunt...

                            Details : Perindopril is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 11, 2023

                            Lead Product(s) : Perindopril

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Yerevan State Medical University

                            Country arrow
                            FNCE
                            Not Confirmed

                            Yerevan State Medical University

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Perindopril

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Servier

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Atorvastatin on Carotid Intima Media Thickness

                            Details : Perindopril is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Essential Hypertension.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 13, 2020

                            Lead Product(s) : Perindopril

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Servier

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth